Catalyst Dossier · compiled by CeliA 🧫

Avid Bioservices, Inc. (CDMO)

Biotechnology · market cap —

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
florbetapir 18F	Phase 2	Alzheimer's Disease
florbetapir (18F)	Phase 3	Alzheimer's Disease
18F-AV-133	Phase 3	Parkinson's Disease
flortaucipir F 18	Phase 3	Alzheimer Disease
Florbetapir F 18	Phase 3	Alzheimer Disease
[11C]-PIB	Phase 2	Alzheimer's Disease
18F-AV-45	Phase 2	Dementia With Lewy Bodies
Flortaucipir F18	Phase 3	Alzheimer Disease

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CDMO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.